-3.26 %
+1.78 %
-3.37 %
-7.28 %
-15.69 %
-7.28 %
+9.90 %
-40.51 %
-82.92 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
45.59M EUR
Turnover
19.48K EUR
P/E (adj.) (26e)
-13.97
EV/EBIT (adj.) (26e)
-12.21
P/B (26e)
5.86
EV/S (26e)
4,995.03
Dividend yield-% (26e)
-
